Skip to main content

Roche drug dramatically reduces bleeds in key haemophilia tests

LONDON, May 21 (Reuters) - Roche's new haemophilia drug Hemlibra dramatically reduced bleeding in a broad population of haemophilia patients, results from two clinical trials showed on Monday, setting it up to take a dominant market position.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.